A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

However, the story of her brother and the end of his life is what she holds dear to her heart. In the workshop, and later in ...

The FTC sued Xlear after it marketed its spray as a covid preventative. The Trump administration dropped the suit, but the ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Getting a cold once or twice a few months is normal, but what about a persistently blocked nose that lingers for weeks and ...

"We are thrilled to bring the SONU Band to Android users now," said Dr. Paramesh Gopi, founder and CEO of SoundHealth. "Our ...

MomMed, a trusted maternal and family wellness brand, today announced a strategic partnership with nasal care innovator ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Lupin launches Ipratropium Bromide Nasal Solution in the US market; eyes expanding complex generics pipeline to over 200 ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...